BioCentury
ARTICLE | Regulation

After COVID-related delays, first approval may come in Europe for bluebird’s Lenti-D 

October 2, 2020 8:44 PM UTC

After a delay in the U.S., EMA could grant bluebird’s Lenti-D its first approval by March 2021.

On Friday, bluebird bio Inc. (NASDAQ:BLUE) announced the agency accepted an MAA for Lenti-D elivaldogene autotemcel (eli-cel) for accelerated assessment to treat cerebral adrenoleukodystrophy (CALD), shaving 60 days off the review process...

BCIQ Company Profiles

bluebird bio Inc.